1. Home
  2. ELS vs INSM Comparison

ELS vs INSM Comparison

Compare ELS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELS
  • INSM
  • Stock Information
  • Founded
  • ELS 1992
  • INSM 1988
  • Country
  • ELS United States
  • INSM United States
  • Employees
  • ELS N/A
  • INSM N/A
  • Industry
  • ELS Real Estate Investment Trusts
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELS Real Estate
  • INSM Health Care
  • Exchange
  • ELS Nasdaq
  • INSM Nasdaq
  • Market Cap
  • ELS 12.5B
  • INSM 14.3B
  • IPO Year
  • ELS 1993
  • INSM 2000
  • Fundamental
  • Price
  • ELS $66.01
  • INSM $81.06
  • Analyst Decision
  • ELS Buy
  • INSM Strong Buy
  • Analyst Count
  • ELS 9
  • INSM 15
  • Target Price
  • ELS $73.78
  • INSM $92.00
  • AVG Volume (30 Days)
  • ELS 1.5M
  • INSM 1.8M
  • Earning Date
  • ELS 01-27-2025
  • INSM 02-20-2025
  • Dividend Yield
  • ELS 3.12%
  • INSM N/A
  • EPS Growth
  • ELS 16.01
  • INSM N/A
  • EPS
  • ELS 1.96
  • INSM N/A
  • Revenue
  • ELS $1,532,414,000.00
  • INSM $363,707,000.00
  • Revenue This Year
  • ELS N/A
  • INSM $20.03
  • Revenue Next Year
  • ELS $3.65
  • INSM $41.61
  • P/E Ratio
  • ELS $33.75
  • INSM N/A
  • Revenue Growth
  • ELS 2.73
  • INSM 19.17
  • 52 Week Low
  • ELS $59.82
  • INSM $21.92
  • 52 Week High
  • ELS $76.60
  • INSM $84.87
  • Technical
  • Relative Strength Index (RSI)
  • ELS 48.94
  • INSM 58.18
  • Support Level
  • ELS $64.90
  • INSM $79.50
  • Resistance Level
  • ELS $67.56
  • INSM $80.28
  • Average True Range (ATR)
  • ELS 1.21
  • INSM 2.98
  • MACD
  • ELS 0.04
  • INSM 0.06
  • Stochastic Oscillator
  • ELS 53.59
  • INSM 63.38

About ELS Equity Lifestyle Properties Inc.

Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Share on Social Networks: